Article
Personalized tacrolimus dose requirement by CYP3A5 but not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantation.
PloS one - 1 Jan 2014
Chen Yi-kuan, Han Long-zhi, Xue Feng, Shen Cong-huan, Lu Jun, Yang Tai-hua, Zhang Jian-jun, Xia Qiang
Abstract excerpt
Tacrolimus (TAC) is the backbone of an immunosuppressive drug used in most solid organ transplant recipients. A single nucleotide polymorphism (SNP) at position 6986G>A in CYP3A5 has been notably involved in the pharmacokinetic variability of TAC. It is hypothesized that CYP3A5 genotyping in patients may provide a guideline for TAC therapeutic regimen. To further evaluate the impact of CYP3A5 variants in donors...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.